Volume | 190,174 |
|
|||||
News | (2) | ||||||
Day High | 5.26 | Low High |
|||||
Day Low | 5.03 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Zevra Therapeutics Inc | ZVRA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.19 | 5.03 | 5.26 | 5.03 | 5.16 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,018 | 190,174 | $ 5.09 | $ 968,278 | - | 3.89 - 7.28 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:45:35 | 10 | $ 5.02 | USD |
Zevra Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
182.54M | 36.22M | - | 27.46M | -46.05M | -1.27 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Zevra Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ZVRA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.66 | 5.30 | 4.6136 | 5.06 | 230,078 | 0.37 | 7.94% |
1 Month | 4.90 | 5.30 | 4.39 | 4.76 | 193,817 | 0.13 | 2.65% |
3 Months | 6.17 | 7.28 | 4.39 | 5.64 | 246,116 | -1.14 | -18.48% |
6 Months | 4.44 | 7.28 | 3.89 | 5.56 | 254,405 | 0.59 | 13.29% |
1 Year | 4.86 | 7.28 | 3.89 | 5.36 | 228,915 | 0.17 | 3.50% |
3 Years | 5.65 | 7.28 | 3.89 | 5.32 | 234,249 | -0.62 | -10.97% |
5 Years | 5.65 | 7.28 | 3.89 | 5.32 | 234,249 | -0.62 | -10.97% |
Zevra Therapeutics Description
Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and commercial stage assets. It employs its LAT platform technology to create a portfolio of approved products. Its product candidates include Arimoclomol, KP1077IH, KP1077N and AZSTARYS. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company's prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older. |